Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-25

AUTHORS

Yung-Jue Bang, Yoon-Koo Kang, Daniel V. Catenacci, Kei Muro, Charles S. Fuchs, Ravit Geva, Hiroki Hara, Talia Golan, Marcelo Garrido, Shadia I. Jalal, Christophe Borg, Toshihiko Doi, Harry H. Yoon, Mary J. Savage, Jiangdian Wang, Rita P. Dalal, Sukrut Shah, Zev A. Wainberg, Hyun Cheol Chung

ABSTRACT

BACKGROUND: The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented. METHODS: Patients ≥ 18 years old had previously untreated recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Cohort 3 (monotherapy) had programmed death receptor 1 combined positive score ≥ 1. Cohort 2 (combination therapy) received pembrolizumab 200 mg on day 1, cisplatin 80 mg/m2 on day 1 (up to 6 cycles), and 5-fluorouracil 800 mg/m2 on days 1-5 of each 3-week cycle (or capecitabine 1000 mg/m2 twice daily in Japan). Primary end points were safety (combination therapy) and objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by central review, and safety (monotherapy). RESULTS: In the combination therapy and monotherapy cohorts, 25 and 31 patients were enrolled; median follow-up was 13.8 months (range 1.8-24.1) and 17.5 months (range 1.7-20.7), respectively. In the combination therapy cohort, grade 3/4 treatment-related adverse events occurred in 19 patients (76.0%); none were fatal. In the monotherapy cohort, grade 3-5 treatment-related adverse events occurred in seven patients (22.6%); one death was attributed to a treatment-related adverse event (pneumonitis). The objective response rate was 60.0% [95% confidence interval (CI), 38.7-78.9] (combination therapy) and 25.8% (95% CI 11.9-44.6) (monotherapy). CONCLUSIONS: Pembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma. CLINICAL TRIAL: ClinicalTrials.gov NCT02335411. More... »

PAGES

1-10

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10120-018-00909-5

DOI

http://dx.doi.org/10.1007/s10120-018-00909-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112985256

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30911859


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Seoul National University", 
          "id": "https://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Internal Medicine, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bang", 
        "givenName": "Yung-Jue", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asan Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413967.e", 
          "name": [
            "Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kang", 
        "givenName": "Yoon-Koo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Chicago", 
          "id": "https://www.grid.ac/institutes/grid.170205.1", 
          "name": [
            "Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Catenacci", 
        "givenName": "Daniel V.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aichi Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Muro", 
        "givenName": "Kei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fuchs", 
        "givenName": "Charles S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Geva", 
        "givenName": "Ravit", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Saitama Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.416695.9", 
          "name": [
            "Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hara", 
        "givenName": "Hiroki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tel Aviv University", 
          "id": "https://www.grid.ac/institutes/grid.12136.37", 
          "name": [
            "Department of Oncology, The Oncology Institute at the Chaim Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Golan", 
        "givenName": "Talia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pontifical Catholic University of Chile", 
          "id": "https://www.grid.ac/institutes/grid.7870.8", 
          "name": [
            "Hematology and Medical Oncology, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garrido", 
        "givenName": "Marcelo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Indiana University \u2013 Purdue University Indianapolis", 
          "id": "https://www.grid.ac/institutes/grid.257413.6", 
          "name": [
            "Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jalal", 
        "givenName": "Shadia I.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Besan\u00e7on", 
          "id": "https://www.grid.ac/institutes/grid.411158.8", 
          "name": [
            "Department of Medical Oncology, University Hospital of Besan\u00e7on, Besancon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Borg", 
        "givenName": "Christophe", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.272242.3", 
          "name": [
            "Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Kashiwa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Doi", 
        "givenName": "Toshihiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoon", 
        "givenName": "Harry H.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Savage", 
        "givenName": "Mary J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Jiangdian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dalal", 
        "givenName": "Rita P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shah", 
        "givenName": "Sukrut", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California Los Angeles", 
          "id": "https://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Division of Hematology Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wainberg", 
        "givenName": "Zev A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yonsei University", 
          "id": "https://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "Hyun Cheol", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.18632/oncotarget.8169", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003612958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70102-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003770145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.acthis.2006.01.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006068474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.4706", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008798214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.yexmp.2014.03.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009382678"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009962018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010815314", 
          "https://doi.org/10.1038/sj.bjc.6605319"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010815314", 
          "https://doi.org/10.1038/sj.bjc.6605319"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.60.1799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011146341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa073149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014019609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/dddt.s75152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016997768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.29210", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018963471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0032542", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019131576"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)00175-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020208654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.13.9378", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023463275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.8429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023864538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu472", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031429641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.thorsurg.2014.12.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032347522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.immuni.2013.06.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033361778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci40269", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036150645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-065x.2010.00923.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037331051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-065x.2010.00923.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037331051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ni.2392", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037520538", 
          "https://doi.org/10.1038/ni.2392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-014-0701-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039233221", 
          "https://doi.org/10.1007/s10147-014-0701-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3390/jcm5100084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042480255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30498-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043568396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053015328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/biomet/26.4.404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059415719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079330788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.6_suppl.398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084255094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0189848", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100101699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2018.0013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101546919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2018.0013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101546919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2018.0013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101546919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)31257-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104380546"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-25", 
    "datePublishedReg": "2019-03-25", 
    "description": "BACKGROUND: The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab\u2009\u00b1\u2009chemotherapy in advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented.\nMETHODS: Patients \u2265\u200918\u00a0years old had previously untreated recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Cohort 3 (monotherapy) had programmed death receptor 1 combined positive score \u2265\u20091. Cohort 2 (combination therapy) received pembrolizumab 200\u00a0mg on day 1, cisplatin 80\u00a0mg/m2 on day 1 (up to 6 cycles), and 5-fluorouracil 800\u00a0mg/m2 on days 1-5 of each 3-week cycle (or capecitabine 1000\u00a0mg/m2 twice daily in Japan). Primary end points were safety (combination therapy) and objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by central review, and safety (monotherapy).\nRESULTS: In the combination therapy and monotherapy cohorts, 25 and 31 patients were enrolled; median follow-up was 13.8\u00a0months (range 1.8-24.1) and 17.5\u00a0months (range 1.7-20.7), respectively. In the combination therapy cohort, grade 3/4 treatment-related adverse events occurred in 19 patients (76.0%); none were fatal. In the monotherapy cohort, grade 3-5 treatment-related adverse events occurred in seven patients (22.6%); one death was attributed to a treatment-related adverse event (pneumonitis). The objective response rate was 60.0% [95% confidence interval (CI), 38.7-78.9] (combination therapy) and 25.8% (95% CI 11.9-44.6) (monotherapy).\nCONCLUSIONS: Pembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma.\nCLINICAL TRIAL: ClinicalTrials.gov NCT02335411.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10120-018-00909-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1020959", 
        "issn": [
          "1436-3291", 
          "1436-3305"
        ], 
        "name": "Gastric Cancer", 
        "type": "Periodical"
      }
    ], 
    "name": "Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study", 
    "pagination": "1-10", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "55bf470b3ca6d7a14aeeb6c0744fca45e2f0ee0e397c5f295a3dbe461b4dc896"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30911859"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100886238"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10120-018-00909-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112985256"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10120-018-00909-5", 
      "https://app.dimensions.ai/details/publication/pub.1112985256"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000366_0000000366/records_112076_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10120-018-00909-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10120-018-00909-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10120-018-00909-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10120-018-00909-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10120-018-00909-5'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      21 PREDICATES      57 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10120-018-00909-5 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nb0962850fdd24a79a1a12fef7ee4537f
4 schema:citation sg:pub.10.1007/s10147-014-0701-7
5 sg:pub.10.1038/ni.2392
6 sg:pub.10.1038/sj.bjc.6605319
7 https://doi.org/10.1001/jamaoncol.2018.0013
8 https://doi.org/10.1002/ijc.29210
9 https://doi.org/10.1016/j.acthis.2006.01.003
10 https://doi.org/10.1016/j.immuni.2013.06.014
11 https://doi.org/10.1016/j.thorsurg.2014.12.003
12 https://doi.org/10.1016/j.yexmp.2014.03.005
13 https://doi.org/10.1016/s0140-6736(18)31257-1
14 https://doi.org/10.1016/s1470-2045(13)70102-5
15 https://doi.org/10.1016/s1470-2045(16)00175-3
16 https://doi.org/10.1016/s1470-2045(16)30498-3
17 https://doi.org/10.1056/nejmoa073149
18 https://doi.org/10.1093/annonc/mdn166
19 https://doi.org/10.1093/annonc/mdn717
20 https://doi.org/10.1093/annonc/mdu472
21 https://doi.org/10.1093/annonc/mdw350
22 https://doi.org/10.1093/biomet/26.4.404
23 https://doi.org/10.1111/j.1600-065x.2010.00923.x
24 https://doi.org/10.1172/jci40269
25 https://doi.org/10.1200/jco.2006.06.8429
26 https://doi.org/10.1200/jco.2007.13.9378
27 https://doi.org/10.1200/jco.2009.25.4706
28 https://doi.org/10.1200/jco.2014.60.1799
29 https://doi.org/10.1200/jco.2017.35.6_suppl.398
30 https://doi.org/10.1371/journal.pone.0032542
31 https://doi.org/10.1371/journal.pone.0189848
32 https://doi.org/10.18632/oncotarget.8169
33 https://doi.org/10.2147/dddt.s75152
34 https://doi.org/10.3390/jcm5100084
35 schema:datePublished 2019-03-25
36 schema:datePublishedReg 2019-03-25
37 schema:description BACKGROUND: The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented. METHODS: Patients ≥ 18 years old had previously untreated recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Cohort 3 (monotherapy) had programmed death receptor 1 combined positive score ≥ 1. Cohort 2 (combination therapy) received pembrolizumab 200 mg on day 1, cisplatin 80 mg/m2 on day 1 (up to 6 cycles), and 5-fluorouracil 800 mg/m2 on days 1-5 of each 3-week cycle (or capecitabine 1000 mg/m2 twice daily in Japan). Primary end points were safety (combination therapy) and objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by central review, and safety (monotherapy). RESULTS: In the combination therapy and monotherapy cohorts, 25 and 31 patients were enrolled; median follow-up was 13.8 months (range 1.8-24.1) and 17.5 months (range 1.7-20.7), respectively. In the combination therapy cohort, grade 3/4 treatment-related adverse events occurred in 19 patients (76.0%); none were fatal. In the monotherapy cohort, grade 3-5 treatment-related adverse events occurred in seven patients (22.6%); one death was attributed to a treatment-related adverse event (pneumonitis). The objective response rate was 60.0% [95% confidence interval (CI), 38.7-78.9] (combination therapy) and 25.8% (95% CI 11.9-44.6) (monotherapy). CONCLUSIONS: Pembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma. CLINICAL TRIAL: ClinicalTrials.gov NCT02335411.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf sg:journal.1020959
42 schema:name Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
43 schema:pagination 1-10
44 schema:productId N255ef4ce55e245c88cc8a8d774422c80
45 N47b9bc15a0e14d11876b96254280884f
46 N80cc1e3d83214a028faf410e4deecbff
47 Na4251a5153eb41edb0da143d5d9e5389
48 Ndf57515efc234e20aad78cfb3c68e757
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112985256
50 https://doi.org/10.1007/s10120-018-00909-5
51 schema:sdDatePublished 2019-04-11T13:06
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N03bd67e6181f4184bd05923c0e99f292
54 schema:url https://link.springer.com/10.1007%2Fs10120-018-00909-5
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N03bd67e6181f4184bd05923c0e99f292 schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 N0542f9643b8145088259f2122d89df9d rdf:first N5ab8dd282c95428aae0f9dcf9d6728e4
61 rdf:rest Nea7d0aede0774a59bd86d4bdf715a86b
62 N08e0ed0be34441b1ad936a4511c06081 rdf:first N2e53833cc60245b685baf1c74cdfe3b0
63 rdf:rest Nb852bc3e76dd4375a3a37962c070a8cd
64 N09e98064b8df49e5b0e1d80d7b416420 schema:affiliation https://www.grid.ac/institutes/grid.31501.36
65 schema:familyName Bang
66 schema:givenName Yung-Jue
67 rdf:type schema:Person
68 N196b7325829d42d9acb6a3733e7fbb76 rdf:first Nc1f04ff5083544d08861e10cbe28508c
69 rdf:rest Nb317f98d007740aab60501754b77bde0
70 N1ae9914a57514caba14aa97bc1cd1835 rdf:first Nc9552132c3ad4ade8df1a48f513b1287
71 rdf:rest N20ab87a53c2b4fcabcfaec1171280a5f
72 N1b491ed1dd4b43e4bc0723bcd0e9f62c schema:affiliation https://www.grid.ac/institutes/grid.272242.3
73 schema:familyName Doi
74 schema:givenName Toshihiko
75 rdf:type schema:Person
76 N1bd1bec2eb9d4361adec5387ba325e02 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
77 schema:familyName Wang
78 schema:givenName Jiangdian
79 rdf:type schema:Person
80 N20ab87a53c2b4fcabcfaec1171280a5f rdf:first N6811ddd6d8194e9cad705a6d5fe3763b
81 rdf:rest rdf:nil
82 N255ef4ce55e245c88cc8a8d774422c80 schema:name nlm_unique_id
83 schema:value 100886238
84 rdf:type schema:PropertyValue
85 N2650906f41234ca5addeb33ba50be7c4 rdf:first Ne8ee10e24b52440cb500513384e14343
86 rdf:rest Nde8aa3cc0f2743f7856295e02d2bbe39
87 N2b5012eea89f40088f46ec6c28da724a schema:affiliation https://www.grid.ac/institutes/grid.417993.1
88 schema:familyName Shah
89 schema:givenName Sukrut
90 rdf:type schema:Person
91 N2e53833cc60245b685baf1c74cdfe3b0 schema:affiliation https://www.grid.ac/institutes/grid.7870.8
92 schema:familyName Garrido
93 schema:givenName Marcelo
94 rdf:type schema:Person
95 N47b9bc15a0e14d11876b96254280884f schema:name pubmed_id
96 schema:value 30911859
97 rdf:type schema:PropertyValue
98 N5381bb757d994356995105ebbfdb9304 rdf:first N95a45398babb422883ceb9fcbdd793b8
99 rdf:rest N2650906f41234ca5addeb33ba50be7c4
100 N5620c067e28447d4a69cc250d8b42865 rdf:first N1b491ed1dd4b43e4bc0723bcd0e9f62c
101 rdf:rest Nb682ad6ea4a642b0bfb07c0dab55aaad
102 N5ab8dd282c95428aae0f9dcf9d6728e4 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
103 schema:familyName Dalal
104 schema:givenName Rita P.
105 rdf:type schema:Person
106 N6119da516f4b4854b7745660e20fb9df rdf:first N8de05f0a26fb46c9b7825ae4d1346dff
107 rdf:rest N08e0ed0be34441b1ad936a4511c06081
108 N6811ddd6d8194e9cad705a6d5fe3763b schema:affiliation https://www.grid.ac/institutes/grid.15444.30
109 schema:familyName Chung
110 schema:givenName Hyun Cheol
111 rdf:type schema:Person
112 N694826d4bebe48678dbf58d5e1d66665 rdf:first Nb4b18fbd579d4d8091e477a3ddaa79ea
113 rdf:rest Nad7efd286f0a4028acf73cdcaa25d8df
114 N75e68872abbd4e3b802bfaaca118b8c7 schema:affiliation https://www.grid.ac/institutes/grid.257413.6
115 schema:familyName Jalal
116 schema:givenName Shadia I.
117 rdf:type schema:Person
118 N80cc1e3d83214a028faf410e4deecbff schema:name readcube_id
119 schema:value 55bf470b3ca6d7a14aeeb6c0744fca45e2f0ee0e397c5f295a3dbe461b4dc896
120 rdf:type schema:PropertyValue
121 N88147e2935aa4637856d1029003b8d31 schema:affiliation Nee7ea491b7d04ee59a1ac523bdab24f1
122 schema:familyName Geva
123 schema:givenName Ravit
124 rdf:type schema:Person
125 N8b81af543c4943c1be61a078f8b0b11e schema:affiliation https://www.grid.ac/institutes/grid.411158.8
126 schema:familyName Borg
127 schema:givenName Christophe
128 rdf:type schema:Person
129 N8de05f0a26fb46c9b7825ae4d1346dff schema:affiliation https://www.grid.ac/institutes/grid.12136.37
130 schema:familyName Golan
131 schema:givenName Talia
132 rdf:type schema:Person
133 N8fb220103d1647c9913364188b63e023 schema:affiliation https://www.grid.ac/institutes/grid.170205.1
134 schema:familyName Catenacci
135 schema:givenName Daniel V.
136 rdf:type schema:Person
137 N94dd2324f8b747b48f6a5877e414b126 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
138 schema:familyName Yoon
139 schema:givenName Harry H.
140 rdf:type schema:Person
141 N95a45398babb422883ceb9fcbdd793b8 schema:affiliation https://www.grid.ac/institutes/grid.410800.d
142 schema:familyName Muro
143 schema:givenName Kei
144 rdf:type schema:Person
145 N99c6293ab7274f5998def336a5655741 schema:affiliation https://www.grid.ac/institutes/grid.416695.9
146 schema:familyName Hara
147 schema:givenName Hiroki
148 rdf:type schema:Person
149 Na4251a5153eb41edb0da143d5d9e5389 schema:name dimensions_id
150 schema:value pub.1112985256
151 rdf:type schema:PropertyValue
152 Nad7efd286f0a4028acf73cdcaa25d8df rdf:first N8fb220103d1647c9913364188b63e023
153 rdf:rest N5381bb757d994356995105ebbfdb9304
154 Nb0962850fdd24a79a1a12fef7ee4537f rdf:first N09e98064b8df49e5b0e1d80d7b416420
155 rdf:rest N694826d4bebe48678dbf58d5e1d66665
156 Nb317f98d007740aab60501754b77bde0 rdf:first N1bd1bec2eb9d4361adec5387ba325e02
157 rdf:rest N0542f9643b8145088259f2122d89df9d
158 Nb4b18fbd579d4d8091e477a3ddaa79ea schema:affiliation https://www.grid.ac/institutes/grid.413967.e
159 schema:familyName Kang
160 schema:givenName Yoon-Koo
161 rdf:type schema:Person
162 Nb682ad6ea4a642b0bfb07c0dab55aaad rdf:first N94dd2324f8b747b48f6a5877e414b126
163 rdf:rest N196b7325829d42d9acb6a3733e7fbb76
164 Nb852bc3e76dd4375a3a37962c070a8cd rdf:first N75e68872abbd4e3b802bfaaca118b8c7
165 rdf:rest Nd26020086f734743a8b937faab7f4264
166 Nc1f04ff5083544d08861e10cbe28508c schema:affiliation https://www.grid.ac/institutes/grid.417993.1
167 schema:familyName Savage
168 schema:givenName Mary J.
169 rdf:type schema:Person
170 Nc9552132c3ad4ade8df1a48f513b1287 schema:affiliation https://www.grid.ac/institutes/grid.19006.3e
171 schema:familyName Wainberg
172 schema:givenName Zev A.
173 rdf:type schema:Person
174 Nd26020086f734743a8b937faab7f4264 rdf:first N8b81af543c4943c1be61a078f8b0b11e
175 rdf:rest N5620c067e28447d4a69cc250d8b42865
176 Nde8aa3cc0f2743f7856295e02d2bbe39 rdf:first N88147e2935aa4637856d1029003b8d31
177 rdf:rest Ne0d12eefc5c645248cfd5a837557b5c5
178 Ndf57515efc234e20aad78cfb3c68e757 schema:name doi
179 schema:value 10.1007/s10120-018-00909-5
180 rdf:type schema:PropertyValue
181 Ne0d12eefc5c645248cfd5a837557b5c5 rdf:first N99c6293ab7274f5998def336a5655741
182 rdf:rest N6119da516f4b4854b7745660e20fb9df
183 Ne8ee10e24b52440cb500513384e14343 schema:affiliation https://www.grid.ac/institutes/grid.433818.5
184 schema:familyName Fuchs
185 schema:givenName Charles S.
186 rdf:type schema:Person
187 Nea7d0aede0774a59bd86d4bdf715a86b rdf:first N2b5012eea89f40088f46ec6c28da724a
188 rdf:rest N1ae9914a57514caba14aa97bc1cd1835
189 Nee7ea491b7d04ee59a1ac523bdab24f1 schema:name Department of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
190 rdf:type schema:Organization
191 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
192 schema:name Medical and Health Sciences
193 rdf:type schema:DefinedTerm
194 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
195 schema:name Oncology and Carcinogenesis
196 rdf:type schema:DefinedTerm
197 sg:journal.1020959 schema:issn 1436-3291
198 1436-3305
199 schema:name Gastric Cancer
200 rdf:type schema:Periodical
201 sg:pub.10.1007/s10147-014-0701-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039233221
202 https://doi.org/10.1007/s10147-014-0701-7
203 rdf:type schema:CreativeWork
204 sg:pub.10.1038/ni.2392 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037520538
205 https://doi.org/10.1038/ni.2392
206 rdf:type schema:CreativeWork
207 sg:pub.10.1038/sj.bjc.6605319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010815314
208 https://doi.org/10.1038/sj.bjc.6605319
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1001/jamaoncol.2018.0013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101546919
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1002/ijc.29210 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018963471
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/j.acthis.2006.01.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006068474
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/j.immuni.2013.06.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033361778
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/j.thorsurg.2014.12.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032347522
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/j.yexmp.2014.03.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009382678
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s0140-6736(18)31257-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104380546
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/s1470-2045(13)70102-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003770145
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/s1470-2045(16)00175-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020208654
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1016/s1470-2045(16)30498-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043568396
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1056/nejmoa073149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014019609
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1093/annonc/mdn166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009962018
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1093/annonc/mdn717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053015328
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1093/annonc/mdu472 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031429641
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1093/annonc/mdw350 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079330788
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1093/biomet/26.4.404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059415719
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1111/j.1600-065x.2010.00923.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037331051
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1172/jci40269 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036150645
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2006.06.8429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023864538
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2007.13.9378 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023463275
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2009.25.4706 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008798214
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2014.60.1799 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011146341
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1200/jco.2017.35.6_suppl.398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084255094
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1371/journal.pone.0032542 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019131576
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1371/journal.pone.0189848 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100101699
259 rdf:type schema:CreativeWork
260 https://doi.org/10.18632/oncotarget.8169 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003612958
261 rdf:type schema:CreativeWork
262 https://doi.org/10.2147/dddt.s75152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016997768
263 rdf:type schema:CreativeWork
264 https://doi.org/10.3390/jcm5100084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042480255
265 rdf:type schema:CreativeWork
266 https://www.grid.ac/institutes/grid.12136.37 schema:alternateName Tel Aviv University
267 schema:name Department of Oncology, The Oncology Institute at the Chaim Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.15444.30 schema:alternateName Yonsei University
270 schema:name Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.170205.1 schema:alternateName University of Chicago
273 schema:name Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL, USA
274 rdf:type schema:Organization
275 https://www.grid.ac/institutes/grid.19006.3e schema:alternateName University of California Los Angeles
276 schema:name Division of Hematology Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
277 rdf:type schema:Organization
278 https://www.grid.ac/institutes/grid.257413.6 schema:alternateName Indiana University – Purdue University Indianapolis
279 schema:name Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
280 rdf:type schema:Organization
281 https://www.grid.ac/institutes/grid.272242.3 schema:alternateName National Cancer Centre
282 schema:name Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Kashiwa, Japan
283 rdf:type schema:Organization
284 https://www.grid.ac/institutes/grid.31501.36 schema:alternateName Seoul National University
285 schema:name Department of Internal Medicine, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea
286 rdf:type schema:Organization
287 https://www.grid.ac/institutes/grid.410800.d schema:alternateName Aichi Cancer Center
288 schema:name Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
289 rdf:type schema:Organization
290 https://www.grid.ac/institutes/grid.411158.8 schema:alternateName Centre Hospitalier Universitaire de Besançon
291 schema:name Department of Medical Oncology, University Hospital of Besançon, Besancon, France
292 rdf:type schema:Organization
293 https://www.grid.ac/institutes/grid.413967.e schema:alternateName Asan Medical Center
294 schema:name Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.416695.9 schema:alternateName Saitama Cancer Center
297 schema:name Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
298 rdf:type schema:Organization
299 https://www.grid.ac/institutes/grid.417993.1 schema:alternateName MSD (United States)
300 schema:name Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.433818.5 schema:alternateName Yale Cancer Center
303 schema:name Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.66875.3a schema:alternateName Mayo Clinic
306 schema:name Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.7870.8 schema:alternateName Pontifical Catholic University of Chile
309 schema:name Hematology and Medical Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...